title: Linezolid for XDR-TB--Final Study Outcomes.
authors.affiliation: International Tuberculosis Research Center, Changwon, South Korea.
authors.forename: Myungsun
authors.initials: M
authors.lastname: Lee
authors.forename: Sang Nae
authors.initials: SN
authors.lastname: Cho
authors.forename: Clifton E
authors.initials: CE
authors.lastname: Barry
authors.forename: Taeksun
authors.initials: T
authors.lastname: Song
authors.forename: Youngran
authors.initials: Y
authors.lastname: Kim
authors.forename: Ina
authors.initials: I
authors.lastname: Jeong
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D023303:Oxazolidinones / Q000008:administration & dosage*; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000995:Antitubercular Agents; D023303:Oxazolidinones; D011500:Protein Synthesis Inhibitors; D000069349:Linezolid